Background: Amifostine has reduced toxicities associated with radiation therapy and platinum-based chemotherapy. In a phase II randomized trial, we investigated the ability of amifostine to reduce the toxicity of carboplatin plus radiotherapy (RCT) in patients with head and neck cancer.
Introduction
Radiotherapy (RT) to the head and neck has significant acute and chronic toxic effects in many patients [1] and the most common dose-limiting toxicity is mucositis, causing severe morbidity. Bacterial and fungal infections secondary to mucositis and xerostomia represent a significant risk for the immunocompromised patient [2, 3] , which results in side effects, including difficulty in swallowing and progressive dental caries [4, 5] , Recent studies show that concurrent chemotherapy and radiation therapy, also referred to as radiochemotherapy (RCT), has resulted in better tumour control [6] [7] [8] . However, these more intensive RCT regimens also result in increased toxicity. Whereas mucositis restricts the administration of intensive RCTas an acute toxicity, xerostomia complicates the quality of life of the patients as both an acute and late toxicity that is typically permanent. No treatment modality is currently available that effectively prevents or reduces mucositis and xerostomia. In addition, thrombocytopenia causes delays and discontinuations of RCT-based modalities and cannot be addressed with the currently available colony-stimulating growth factors (CSFs).
Preclinical studies have shown that the aminothiol mercaptoethylamine analogue amifostine (Ethyol 11 '; US Bioscience Inc., West Conshohocken, PA) selectively protected normal cells while preserving the antitumour effects of radiotherapy [9] . Recent animal studies by Dendale et al. [10] , who investigated the topical or systemic administration of amifostine to mice receiving fractionated radiotherapy (four fractions per day for two days), have demonstrated a significantly lower degree of mucositis of the lip and oral cavity related to radiotherapy alone (P < 0.001). Additionally, mice receiving only radiotherapy exhibited severe weight loss with concurrent mucositis, while weight loss in the amifostinetreated mice was substantially reduced.
Other investigators have shown that amifostine protects the rat parotid gland from short-term and long-term chronic damage due to radiation [11, 12] . Clinical work by Liu and Kligerman demonstrated the therapeutic value of amifostine treatment, reporting protection against radiotherapy-induced acute and late toxicities, including mucosal damage and various skin toxicities [13] .
In a phase I study of patients with head and neck cancer receiving radiation therapy the prevention of severe salivary dysfunction [14] with amifostine was reported. In another study examining salivary gland function by 67 Ga uptake, doses as small as 100 mg/m 2 of amifostine protected patients with head and neck cancer from chronic radiation injury. Parotid gland function was preserved throughout the treatments, minimizing the potential for xerostomia [15] .
Amifostine has also demonstrated an ability to reduce the hematologic toxicity associated with platinum and alkylating-agent chemotherapy. In a randomized phase III trial of cisplatin and cyclophosphamide in patients with advanced ovarian cancer, patients pretreated with amifostine had a significantly reduced incidence of neutropenic fever (P -0.019) and required significantly fewer delays in chemotherapy due to hematologic toxicity (P = 0.004) [16] . Additionally, in randomized trials, pretreatment with amifostine significantly shortened the time to platelet recovery (P = 0.04) from carboplatininduced thrombocytopenia [17] .
In the present phase II randomized trial, we investigated the ability of amifostine to protect against the toxic effects of carboplatin administered concurrently with standard fractions of RT while preserving the efficacy of this regimen in the treatment of patients with head and neck cancer.
Study endpoints
Differential blood cell counts, electrolytes, liver transaminase levels, urea and creatinine levels were monitored routinely. Weekly examinations and questioning of all study participants to detect any emergent side effects were recorded according to the World Health Organization (WHO)/Radiation Therapy Oncology Group classification [18] , the Seegenschmidt and Sauer classification or, if needed, the National Cancer Institute guidelines for mucositis, dysphagia, ageusia, xerostomia, dermatitis, pain, nausea, and vomiting. When applicable, objective tumour response was assessed according to the WHO criteria [18] .
Supporting therapies
Patients were treated with appropriate doses of granulocyte colonystimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) for grade 3 leukopenia, analgesia for pain, and antibiotics/fluconazole for bacterial/fungal infections. In the event of excessive mucosal reaction and nutritional deterioration nutritional support was instigated.
Patients and methods

Eligibility criteria
Patients were eligible for this study if they met the following criteria: demonstration of stage III or IV carcinoma (Union Internationale Contre le Cancer classification) of the head and neck, age between 16 and 80 years and no evidence of systemic infection, or liver or renal impairment. There could be no contraindications for treatment with RCT, and their informed consent, either written or verbal, was required prior to study entry.
Treatment protocol
Eligible patients were randomized to receive RCT ± amifostine. Because of patient logistics and to enforce compliance, the practice in this situation was to hospitalize patients during treatment. The selected patients were hospitalized for the duration of this six-week study but were permitted to return home over weekends. At the end of each week, all patients underwent physical examination, and clinical findings and any emerging side effects were documented.
Primary therapy consisted of microlaser surgical tumour resection or conventional tumour excision followed by adjuvant RCT. For patients with inoperable tumours and for those who refused surgery, radiochemotherapy was instituted as definitive treatment. Radiotherapy was given in 2 Gy fractions, five days per week for six weeks, up to a maximum dose of 60 Gy in the primary tumour region and regional lymph nodes of the neck. Patients were exposed to a radiation field that encompassed at least 75% of the major salivary glands.
Chemotherapy consisted of a 20-minute intravenous infusion of carboplatin at a dose of 70 mg/m 2 on days 1 through 5 and 21 through 25 of treatment. Immediately before receiving carboplatin, patients in the amifostine arm were given a rapid 15-minute infusion of amifostine (500 mg) preceded by an antiemetic regimen of 12 mg dexamethasone and 8 mg ondansetron. Amifostine was not administered on the days when RT was administered alone. Eight hours later, an additional 8 mg oral dose of ondansetron was given as required. Radiotherapy was administered subsequent to carboplatin. All patients were closely monitored during amifostine infusions and for the first five minutes of the carboplatin infusions in order to detect any possible side effects of amifostine.
A 500 mg dose of amifostine, based on body surface area, would lie in the range of 250 mg/m" to 340 mg/nr. As these doses are within the range that has been administered prior to daily fractionated radiation therapy in other trials, the 500 mg dose of amifostine was selected for ease of administration as it is the amount of amifostine in one vial.
Statistical analysis
Differences between the two treatment arms were compared using a Mantel-Haenszel chi square statistic, which takes into account the severity as well as the incidence of toxicities reported. Differences in the use of the various supportive therapies were compared using Fisher's exact test.
Results
Twenty-eight patients (14 patients each) were randomized to receive either amifostine plus RCT or RCT alone. At the completion of therapy, none of the amifostinetreated patients, but 12 of 14 (86%) RCT-alone patients experienced grade 3/4 mucositis (P < 0.001). Additionally, the patients pretreated with amifostine had significantly less severe xerostomia (P < 0.001) and thrombocytopenia {P -0.004) than those treated with RCT alone. In view of these positive results, an additional 11 patients were subsequently accrued to the amifostine arm. The results for the 14 patients randomized to RCT are compared with the results for the initial 14 patients randomized to amifostine plus RCT, and for all patients (n = 25) who received amifostine plus RCT. Table 1 summarizes the clinical characteristics of this patient population. Twenty-five men and 14 women with advanced (stage III or IV) squamous cell carcinoma of the head and neck were entered into this study. The patient age ranged from 38 to 77 years, with a median of 61 years. Of the 25 patients on the amifostine arm, 15 received RCT as adjuvant treatment and 10 received RCT as primary treatment. Of the 14 patients treated with RCT alone, 11 received RCT as adjuvant treatment and three received RCT as primary treatment. Using the WHO criteria, none of the patients enrolled had hematologic toxicity at baseline. The median follow-up time for this study is in excess of 12 months.
Non-hematologic toxicity
As shown in Table 2 , the incidence and severity of mucositis was significantly reduced by the use of amifostine (P -0.0001). None of the patients pretreated with amifostine developed grade 3 or 4 mucositis and only five patients in this group developed grade 2 mucositis.
Fourteen patients treated with RCT alone developed grade 2 xerostomia (moderate to complete dryness with thick, sticky saliva and markedly altered taste) compared with three of 25 (12%) patients in the amifostine arm (P = 0.0001). Treatment with amifostine also produced significant reductions in the severity of dermatitis (P -0.002), loss of taste (P = 0.0001), and dysphagia {P = 0.001) in comparison to RCT alone. Twelve-month follow-up data available on the first 28 patients randomized show that late grade 2 xerostomia (complete loss of salivary gland flow) was reported in 55% of the patients treated with RCT alone compared with 17% in patients pretreated with amifostine (P = 0.05).
Hematologic toxicity
Treatment with amifostine resulted in significant reductions in the incidence and severity of hematologic toxicity from this regimen of carboplatin and radiation as assessed by thrombocytopenia (P -0.001), leukopenia (P = 0.001), and anemia (P -0.014, Table 3 ). In the amifostine arm, none of the patients developed grade 3 or 4 thrombocytopenia. In contrast, four patients (29%) in the RCT-alone arm experienced grade 3-4 thrombocytopenia (P = 0.012). Additionally, the use of supportive care, e.g., growth factors and antibiotics, was significantly less in the amifostine arm (Table 4) . Ten patients in the RCT-alone arm required treatment with antibiotics compared with seven patients in the amifostine arm (P -0.017). G-CSF was used on seven occasions in the RCTarm compared with three occasions in the amifostine arm (P = 0.019), and GM-CSF was used on seven occasions in the RCT-alone arm compared with one occasion in the amifostine arm (P -0.001).
Treatment response
At the end of the six-week treatment period, six patients in the control arm (43%) were classified as having no evidence of disease and six patients (43%) were classified as having partial responses. Three of the patients who had partial responses at the end of treatment had no evidence of disease at the end of 12 months. Three of the control patients had delayed responses resulting in nine of 14 or 64% of patients in the control arm with no evidence of disease at 12 months. Thus this trial provides no evidence that amifostine negatively impacts the antitumor efficacy of RCT.
Side effects of treatment
Nausea and vomiting, common side effects of amifostine administration, were effectively controlled with antiemetic medications (see Treatment Protocol for description of regimens) and was not observed in either treatment group. Transient decreases in blood pressure were observed in 10 of 25 (40%) patients in the amifostine arm. However, the maximal drop in blood pressure was 20 mm Hg and occurred in two (8%) patients, and neither an interruption in amifostine infusion nor a discontinuation of therapy was required at any time due to hypotension. None of these patients was symptomatic or required additional intravenous fluid due to these transient reductions in blood pressure.
Discussion
It is estimated that 40,000 cases of squamous cell cancer of the head and neck occurred in 1996 [19] . At the time of diagnosis, as many as 75% of patients have advanced disease, stages III to IV. While surgery or radiation or both are considered standard approaches for treatment, the overall cure rate remains at a disappointing 30% [6] .
Various studies have investigated the efficacy of specific chemotherapeutic drugs in patients with head and neck cancer [6, 20] . Collectively, the individual use of cytotoxic agents such as cisplatin, 5-fluorouracil, methotrexate, and bleomycin resulted in only a 15% to 51% response rate. Although the duration of response and the survival rates were not lengthened, combining these drugs did raise the response rate to about 40% in those evaluated. Recently, it has been demonstrated that additional therapies combining single-drug and multidrug chemotherapy with concomitant radiotherapy improve treatment outcomes [7] . The combined approach, termed radiochemotherapy, strives to (1) increase survival while decreasing morbidity and (2) minimize the need for extreme surgical intervention, thereby preserving the affected organs [7] . Additionally, by using such combinational approaches, the goal of eradicating local microscopic and distant micrometastatic disease is furthered, as is the diminution of the incidence of loco-regional and distant relapse [6] .
While these combinations are championed as possibly the most beneficial approaches for improving the response and survival of patients with either advanced resectable or unresectable disease [7] , the ensuing toxicities are severe. Often, interruptions in treatment must be scheduled to permit injured tissues and organs to recover. Patients receiving concomitant radiotherapy and chemotherapy have required a median time of eight weeks to recover from severe (grade 3) mucositis [21] . This is particularly critical in treating head and neck carcinoma, because the side effects of mucositis and xerostomia often minimize compliance and hamper the completion of a protocol.
A recent meta-analysis performed by El-Sayed and Nelson [22] evaluated the efficacy of adding chemotherapy to local surgery, radiotherapy, or both. This report concluded that using chemotherapy in conjunction with other treatments significantly increased tumour response and patient survival, but at the expense of significantly increased treatment-related morbidity. Work performed by Merlano et al. [8, 23] has corroborated the beneficial effects of combined (and alternating) radiochemotherapy.
The successful use of amifostine to protect against various toxicities induced by radiation therapy and chemotherapy used in other cancers has been reported [13, 16] . In head and neck cancer, treatment studies of radioprotection with amifostine have been encouraging. A phase I-II clinical study has been conducted using amifostine (100 mg/m 2 ) as an adjunct to head and neck radiotherapy [14] . Radiation was administered in five equal fractions (1.8 to 2 Gy) over six to seven weeks, with amifostine given within 15 minutes of this irradiation over a six-minute period. Amifostine pretreatment resulted in an improvement of salivary gland function at nine to 12 months with salivary flow rates remaining at approximately 70% of baseline. (This is of interest, since the parotid gland, a purely serous organ is most sensitive to radiation.) A study by Tanaka showed that amifostine at doses as low as 100 mg reduced the mucositis associated with radiation to the head and neck region [24] .
In this phase II trial of patients with head and neck cancer treated with RCT, amifostine (500 mg) was well tolerated and offered significant protection from toxicity related to RCT used alone. Currently, mucositis and xerostomia are the principal toxicities of RCT treatment of head and neck cancer. The mucositis can be severe and painful, leading to secondary complications. Mucositis as well as hematologic toxicities can limit drug doses, hinder compliance, and may diminish treatment response. Xerostomia is typically permanent and negatively impacts the patients'quality of life.
Given the potential sensitivity to radiotherapeutic and chemotherapeutic treatments, the implementation of cytoprotectants such as amifostine in the treatment of head and neck cancers is a logical step in the development of more effective therapies. Our study shows amifositine to be well tolerated and to consistently and significantly reduce the deleterious side effects, specifically mucositis, xerostomia, and hematotoxicity, associated with RCT, and it provides no evidence that amifostine negatively impacts the antitumor efficacy of RCT.
The significant reductions in treatment-limiting adverse events support the use of amifostine during conventional RCT for head and neck cancer and may allow better overall treatment outcome, as is indicated by the better quality of remissions reported in this study. At 12 months, 79% of the amifostine + RCT patients (i.e., 11 of 14 of the original cohort of the amifostine group) were alive and disease-free compared to 64% of the 14 patients treated with RCT alone. Although there are small imbalances that could affect individual comparisons between the two treatment arms in this study, the consistency in results across the various radiationinduced toxicities indicates that the differences in observed toxicities were due to amifostine treatment. Moreover, as all patients received the same dose of carboplatin, the hematologic toxicity would not be affected by these imbalances. These data, as well as the 12-month efficacy data, support amifostine's role as a selective cytoprotective agent for RCT. In view of our positive findings, a larger multicenter phase III randomized trial of RCT with or without amifostine is being conducted.
